Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF) CEO Michael McFadden tells Proactive the Vancouver, Canada-based biopharmaceutical company focused on neurodegenerative disorders is will soon initiate its pivotal trial to treat the symptoms associated with Alzheimer’s disease in 3Q of this year. McFadden says top-line results from its lead drug ALPHA-1062 are targeted for release in Q1 of 2022, putting it on track for an approval in 2023.